Switch to:
Also traded in: Argentina, Brazil, Chile, France, Germany, Mexico, Romania, Switzerland, UK

Latest Guru Trades with MRK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 13.30
MRK's P/E(ttm) is ranked higher than
82% of the 783 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.27 vs. MRK: 13.30 )
Ranked among companies with meaningful P/E(ttm) only.
MRK' s P/E(ttm) Range Over the Past 10 Years
Min: 6.33  Med: 17.55 Max: 133.39
Current: 13.3
6.33
133.39
Forward P/E 12.77
MRK's Forward P/E is ranked higher than
100% of the 412 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.50 vs. MRK: 12.77 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 13.18
MRK's PE(NRI) is ranked higher than
85% of the 554 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.00 vs. MRK: 13.18 )
Ranked among companies with meaningful PE(NRI) only.
MRK' s PE(NRI) Range Over the Past 10 Years
Min: 6.28  Med: 17.40 Max: 133.39
Current: 13.18
6.28
133.39
P/B 3.00
MRK's P/B is ranked lower than
62% of the 936 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.31 vs. MRK: 3.00 )
Ranked among companies with meaningful P/B only.
MRK' s P/B Range Over the Past 10 Years
Min: 1.72  Med: 3.22 Max: 7.25
Current: 3
1.72
7.25
P/S 3.52
MRK's P/S is ranked higher than
100% of the 935 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.47 vs. MRK: 3.52 )
Ranked among companies with meaningful P/S only.
MRK' s P/S Range Over the Past 10 Years
Min: 2.01  Med: 3.18 Max: 5.47
Current: 3.52
2.01
5.47
PFCF 29.15
MRK's PFCF is ranked higher than
52% of the 464 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 29.12 vs. MRK: 29.15 )
Ranked among companies with meaningful PFCF only.
MRK' s PFCF Range Over the Past 10 Years
Min: 7.87  Med: 15.95 Max: 88.93
Current: 29.15
7.87
88.93
POCF 19.80
MRK's POCF is ranked higher than
55% of the 633 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.66 vs. MRK: 19.80 )
Ranked among companies with meaningful POCF only.
MRK' s POCF Range Over the Past 10 Years
Min: 6.68  Med: 13.18 Max: 36.1
Current: 19.8
6.68
36.1
EV-to-EBIT 9.10
MRK's EV-to-EBIT is ranked higher than
82% of the 804 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.88 vs. MRK: 9.10 )
Ranked among companies with meaningful EV-to-EBIT only.
MRK' s EV-to-EBIT Range Over the Past 10 Years
Min: 4.9  Med: 12.90 Max: 52.6
Current: 9.1
4.9
52.6
EV-to-EBITDA 6.62
MRK's EV-to-EBITDA is ranked higher than
87% of the 843 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.62 vs. MRK: 6.62 )
Ranked among companies with meaningful EV-to-EBITDA only.
MRK' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.2  Med: 8.10 Max: 20.4
Current: 6.62
4.2
20.4
PEG 3.33
MRK's PEG is ranked lower than
62% of the 276 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.08 vs. MRK: 3.33 )
Ranked among companies with meaningful PEG only.
MRK' s PEG Range Over the Past 10 Years
Min: 0.89  Med: 4.16 Max: 86.62
Current: 3.33
0.89
86.62
Shiller P/E 20.96
MRK's Shiller P/E is ranked higher than
77% of the 175 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 42.02 vs. MRK: 20.96 )
Ranked among companies with meaningful Shiller P/E only.
MRK' s Shiller P/E Range Over the Past 10 Years
Min: 7.55  Med: 14.77 Max: 24.67
Current: 20.96
7.55
24.67
Current Ratio 1.62
MRK's Current Ratio is ranked lower than
65% of the 713 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.27 vs. MRK: 1.62 )
Ranked among companies with meaningful Current Ratio only.
MRK' s Current Ratio Range Over the Past 10 Years
Min: 1.07  Med: 1.59 Max: 3.7
Current: 1.62
1.07
3.7
Quick Ratio 1.33
MRK's Quick Ratio is ranked lower than
59% of the 713 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.65 vs. MRK: 1.33 )
Ranked among companies with meaningful Quick Ratio only.
MRK' s Quick Ratio Range Over the Past 10 Years
Min: 0.8  Med: 1.24 Max: 3.44
Current: 1.33
0.8
3.44
Days Inventory 111.44
MRK's Days Inventory is ranked higher than
54% of the 643 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 118.46 vs. MRK: 111.44 )
Ranked among companies with meaningful Days Inventory only.
MRK' s Days Inventory Range Over the Past 10 Years
Min: 104.23  Med: 130.49 Max: 205.16
Current: 111.44
104.23
205.16
Days Sales Outstanding 59.27
MRK's Days Sales Outstanding is ranked higher than
64% of the 585 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 75.01 vs. MRK: 59.27 )
Ranked among companies with meaningful Days Sales Outstanding only.
MRK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 44.5  Med: 57.78 Max: 87.87
Current: 59.27
44.5
87.87
Days Payable 49.44
MRK's Days Payable is ranked lower than
69% of the 558 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 72.59 vs. MRK: 49.44 )
Ranked among companies with meaningful Days Payable only.
MRK' s Days Payable Range Over the Past 10 Years
Min: 30.2  Med: 42.08 Max: 90.81
Current: 49.44
30.2
90.81

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.70
MRK's Dividend Yield is ranked higher than
85% of the 688 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.45 vs. MRK: 3.70 )
Ranked among companies with meaningful Dividend Yield only.
MRK' s Dividend Yield Range Over the Past 10 Years
Min: 2.51  Med: 3.99 Max: 6.68
Current: 3.7
2.51
6.68
Dividend Payout 0.48
MRK's Dividend Payout is ranked higher than
65% of the 419 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.32 vs. MRK: 0.48 )
Ranked among companies with meaningful Dividend Payout only.
MRK' s Dividend Payout Range Over the Past 10 Years
Min: 0.15  Med: 0.50 Max: 4.22
Current: 0.48
0.15
4.22
Dividend Growth (3y) 4.30
MRK's Dividend Growth (3y) is ranked lower than
56% of the 280 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.30 vs. MRK: 4.30 )
Ranked among companies with meaningful Dividend Growth (3y) only.
MRK' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 3.20 Max: 14.8
Current: 4.3
0
14.8
Forward Dividend Yield 3.77
MRK's Forward Dividend Yield is ranked higher than
84% of the 610 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. MRK: 3.77 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 4.42
MRK's Yield on cost (5-Year) is ranked higher than
82% of the 686 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.86 vs. MRK: 4.42 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
MRK' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 3  Med: 4.76 Max: 7.97
Current: 4.42
3
7.97
3-Year Average Share Buyback Ratio 1.80
MRK's 3-Year Average Share Buyback Ratio is ranked higher than
95% of the 462 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -2.90 vs. MRK: 1.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MRK' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -13  Med: 1.10 Max: 1.8
Current: 1.8
-13
1.8

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 33.58
MRK's Price/Tangible Book is ranked lower than
96% of the 898 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.67 vs. MRK: 33.58 )
Ranked among companies with meaningful Price/Tangible Book only.
MRK' s Price/Tangible Book Range Over the Past 10 Years
Min: 3.19  Med: 12.04 Max: 3735
Current: 33.58
3.19
3735
Price/Projected FCF 1.16
MRK's Price/Projected FCF is ranked higher than
81% of the 534 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.16 vs. MRK: 1.16 )
Ranked among companies with meaningful Price/Projected FCF only.
MRK' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.75  Med: 1.30 Max: 3.04
Current: 1.16
0.75
3.04
Price/DCF (Earnings Based) 2.94
MRK's Price/DCF (Earnings Based) is ranked lower than
76% of the 127 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.44 vs. MRK: 2.94 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.11
MRK's Price/Median PS Value is ranked higher than
53% of the 906 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.12 vs. MRK: 1.11 )
Ranked among companies with meaningful Price/Median PS Value only.
MRK' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.65  Med: 1.11 Max: 2.04
Current: 1.11
0.65
2.04
Price/Peter Lynch Fair Value 1.05
MRK's Price/Peter Lynch Fair Value is ranked higher than
67% of the 268 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.59 vs. MRK: 1.05 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
MRK' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.97  Med: 1.63 Max: 11.48
Current: 1.05
0.97
11.48
Price/Graham Number 4.44
MRK's Price/Graham Number is ranked lower than
82% of the 685 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.10 vs. MRK: 4.44 )
Ranked among companies with meaningful Price/Graham Number only.
MRK' s Price/Graham Number Range Over the Past 10 Years
Min: 1.08  Med: 3.43 Max: 34.91
Current: 4.44
1.08
34.91
Earnings Yield (Greenblatt) (%) 10.99
MRK's Earnings Yield (Greenblatt) (%) is ranked higher than
54% of the 723 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. MRK: 10.99 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MRK' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.9  Med: 7.80 Max: 20.6
Current: 10.99
1.9
20.6
Forward Rate of Return (Yacktman) (%) 18.50
MRK's Forward Rate of Return (Yacktman) (%) is ranked higher than
54% of the 325 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.77 vs. MRK: 18.50 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
MRK' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 2  Med: 5.40 Max: 15.7
Current: 18.5
2
15.7

More Statistics

Revenue(Mil) $39498
EPS $ 1.56
Beta0.75
Short Percentage of Float1.13%
52-Week Range $45.69 - 61.70
Shares Outstanding(Mil)2793.54

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 40,062 39,970 41,988
EPS($) 3.75 3.82 4.16
EPS without NRI($) 3.75 3.82 4.16

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:MRK.Argentina, MRCK34.Brazil, MRK.Chile, MRK.France, 6MK.Germany, MRK.Mexico, MRK.Romania, MRK.Switzerland, 0QAH.UK,
Merck & Co Inc was incorporated in New Jersey in 1970. The Company is a health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company's operations are mainly managed on a products basis and are comprised of four operating segments, which are the Pharmaceutical, Animal Health, Consumer Care and Alliances segments, and one reportable segment, which is the Pharmaceutical segment. The Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. The Company also has animal health operations that discover, develop, manufacture and market animal health products, including vaccines, which the Company sells to veterinarians, distributors and animal producers. Additionally, the Company has consumer care operations that develop, manufacture and market over-the-counter, foot care and sun care products, which are sold through wholesale and retail drug, food chain and mass merchandiser outlets, as well as club stores and specialty channels. The Company's competitors include other worldwide research-based pharmaceutical companies, smaller research companies with more limited therapeutic focus, and generic drug and consumer health care manufacturers. The Company's activities, including research, preclinical testing, clinical trials and manufacturing and marketing its products, are subject to regulation by numerous federal, state and local governmental authorities in the United States, including the FDA, and by foreign regulatory authorities, including the European Commission.
» More Articles for NYSE:MRK

Headlines

Articles On GuruFocus.com
Richard Snow Makes Huge Increases in Big-Name Stocks Jan 08 2016 
5 Top Stocks of the Outperforming Vanguard Health Care Fund Dec 28 2015 
5 Guru Picks in Volatile Biotech Industry Dec 23 2015 
Kahn Brothers' Largest Sales During 3rd Quarter Dec 22 2015 
Vanguard Raises Stakes in Biogen, Mylan, Merck Nov 15 2015 
Richard Snow Invests in Familiar Names in 3rd Quarter Nov 13 2015 
Merck & Co. Versus AbbVie: Who Is the Winner and Who Is the Loser? Nov 12 2015 
Pfizer to Create a New Pharmaceutical Colossus Nov 05 2015 
Vanguard Health Care Fund Buys Biogen and Mylan, Cuts Pfizer Nov 02 2015 
Charles Brandes' Most Weighted Trades in Q2 2015 Sep 30 2015 

More From Other Websites
Express Scripts Giving 'Extra Scrutiny' to Valeant Prescriptions Feb 12 2016
Sun Pharma to seek FDA re-inspection of Indian drug plant by end-June Feb 12 2016
UK watchdog fines GSK $54 mln over 'pay-for-delay' drug deals Feb 12 2016
The search for yield Feb 11 2016
Kahn Brothers’ Top Stock Picks for Early 2016; Citigroup Inc. (C) Leading the Pack Feb 11 2016
Relypsa: This Biotech Just Released Stunning Data Feb 10 2016
Short Sellers Increase Bets in Major Pharma Feb 10 2016
FDA panel backs lower-cost version of J&J's top-selling drug Feb 09 2016
FDA panel backs lower-cost version of J&J's top-selling drug Feb 09 2016
Pfizer, Reynolds Among Recession Stock Plays — GE, GM For Recovery Feb 09 2016
Pfizer Reported 7% Top Line Growth in 4Q15 Feb 09 2016
Major Developments for Eli Lilly and Co. in 4Q15 Feb 08 2016
The 'Dogs Of The Dow' Are Outperforming The Index, Here's How Too Trade Them Feb 08 2016
Top of The List: Largest Biotech/Pharma Companies and Largest CROs Feb 08 2016
4 Big Dividend Pharmaceutical Stocks to Buy That Are Very Cheap Now Feb 08 2016
Where is Ronald Reagan When You Need Him? Feb 08 2016
These 5 Rocket Stocks Could Blast Higher in February Feb 08 2016
How Analysts View Pfizer and Merck After Earnings Feb 07 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GuruFocus Premium Plus Membership

FEEDBACK